Genetically modified cells manage to save children from leukemia

A recent study published by the “Nature Medicine” magazine revealed new visions, explaining the reason for the absence of leukemia for children for longer periods than others, after undergoing advanced cell treatment. In recent years, the method of genetically modified T -cell therapy, a type of immune, is designed to target leukemia, a fixed treatment option for children with acute or unknown leukemia. In that type of treatment, T -cells from the patient’s blood are extracted by a process called ‘white cells’, and in the laboratory, the TT cells that are genetically collected to print receptors, ‘chemical antigens’ on their surface, and these receptors are designed to identify certain proteins or antigens in cancer cells. Thereafter, modified T -cells are implanted and expanded in the laboratory, which leads to an increase in their number, then injected an intravenously into the patient’s body, and as soon as they enter, they get to know and stimulate the targeted cancer cells and begin a strong immune response to cancer. This may include the release of toxic substances for cells and the recruitment of other immune cells to attack cancer cells, as the treatment of modified T -cells has shown remarkable success in the treatment of some types of leukemia and certain types of lymphoma. The validity of the T -cells and sees the new study conducted by researchers at the University of California, Great Ormond Street Hospital and Wilcum singer Institute, that one of the most important factors that determines whether the treatment is long -term leukemia is the length of the time of the modified T -cells in the body. Until now, little is known about the reason for these cells that remain in the body, and whether it is likely that the treatment works in the long run and effective. The lead author of the study, Nathaniel Anderson, of the Wilcum singer Institute, said in a statement that the team “for the first time managed to decipher the T -cell continuity code in the bodies of some children and to deliver the first proof of the cause of the important case that contributes to the absence of cancer after treatment.” In turn, the author, Sarah Juraceyan, a blood diseases consultant at Great Ormond Street Hospital, said for the first time ‘the characteristics of the immunotherapy cells with a long responsible T -cells that not only treated children with acute leukemia but also treated in adults with the same mechanism. Carpall experience, and in the study, the team has been treating them with genetically modified T cells for years after they have a picture of why some of them remain in the body in the body, as this work provides the first starting point for the reason for the continued presence of some genetically modified T -cells. Using techniques that analyze individual cells at a genetic level to understand what they do, scientists could determine a unique signature in immunotherapy cells that remain in the body for a long time, as the signature indicates that long -term cells in the blood change in another condition that enables them to monitor the patient’s body in search of cancer cells. The team was able to study the cells of ten children who were registered for up to five years in the carriage experience, after undergoing the original treatment of modified T cells, which made them a new understanding of the reason for some of these cells in the patient’s blood course, and why they faded early with others, which in some cases could return cancer. The researchers have identified specific genetic changes or patterns associated with the long -term and effective cells, as the understanding of these molecular properties can provide visions on how to continue the treatment of immune cells and their function in the body, which can help improve T -cell treatments and improve their long -term cancer patients in cancer patients. They have also identified the most important genes in the modified T -cells that enable them to stay in the body for a long time, and most importantly, these genes provide a starting point for future studies to determine the signs of stability in modified T -cell treatments when produced and ultimately improves its effectiveness. Also read: